“We are extremely excited about sharing the unique experience of the Crunch brand with the residents surrounding our newest location in Marietta,” said CR Fitness Holdings CEO Tony Scrimale. “We can’t wait to show you how we combine top-notch equipment, extraordinary classes, and personal training at an unbeatable value.”
Fusing fitness with entertainment, Crunch Marietta features top-quality strength training equipment, an extensive selection of premier cardio equipment, a Group Fitness Studio, HIITZone™, a Cycling Studio, a Training Hub, Dry Saunas, HydroMassage®, tanning facilities, and spacious locker rooms, among other amenities.
The CR Fitness team, led by industry giants Vince Julian, Geoff Dyer, Jeff Dotson, and Tony Scrimale, boasts a collective experience of over 150 years in the fitness realm. Today, the CR Fitness family manages 57 Crunch Fitness locations, spanning across Florida, Georgia, North Carolina, and Texas. The upcoming debut of Crunch Marietta as CR Fitness’ location #58, will be the 12th Crunch Fitness location to open in the Atlanta region, marking a significant addition. This expansion not only brings a new fitness destination but also contributes to creating more employment opportunities.
To kickstart the festivities and provide our community with a preview of what’s to come, Crunch Marietta will host a “Sneak Peek Sip Sip” event on Thursday, October 26 from 6 p.m. to 9 p.m. Crunch Fitness invites all to join in the festivities and begin your journey to a healthier, happier lifestyle.
Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and treatment development ▶ New focus on NK cell therapy for conquering cancer ▶ GC Cell seizes the opportunity to share its cell gene therapy technology and capabilities globally ▶ Development…
A focus on building community for patients, survivors, caregivers, and healthcare professionals.
A focus on taking an active role in your healthcare.
Hearing from people with lived experiences similar to yours.
Understanding how patient voice makes a difference in healthcare and how to become part of the change.
Learning how to navigate and overcome obstacles related to your mental health during and after a diagnosis.
In its first four years, GVCC has brought together more than 8,000 individuals from nearly 55 countries, 200+ different speakers who bring their own unique experiences to the discussions, and over 100 non-profit patient advocacy organizations participate in sharing resources and engagement.
“We took feedback from previous years and are really focusing on patient empowerment through self-advocacy in healthcare for GVCC 2023,” said Jessica Carroll, Senior Vice President of Administration at Gryt Health.
GVCC 2023 will be hosted on Gryt Health’s proprietary virtual technology platform that encourages interaction. The system leverages Zoom meeting functionality for presentations. Registration for GVCC 2023 is free and available to all at https://grythealth.com/.
About Gryt Health Inc
Gryt Health’s priority is to help you find and use your voice to navigate your own diagnosis, help your peers, and change health systems. Your experience and story matters. Our online space was designed with this in mind. Our company was started by patients and caregivers, for patients and caregivers. We work with bold companies who put the patient and caregiver at the center of everything they do. Together, we are moving healthcare forward with the people and organizations we respect most. Visit https://grythealth.com to learn more.
“Dr. Greenspun brings an exceptional perspective to our organization. He’s served not just the clinical side, but across nearly every industry. He is the perfect choice to lead this innovative new health and well-being practice, and we’re thrilled work alongside him,” said Tom Barnes, managing partner. “We are very excited to introduce this new area of expertise to our clients. We have all learned a lot over the past few years, and more and more organizations grasp how broadly health impacts their people, products and environment.”
An experienced chief medical officer himself, Greenspun has held executive roles at Deloitte, Dell, Northrop Grumman, Korn Ferry, and Guidehouse. As a cardiac anesthesiologist, Greenspun has practiced in major academic medical centers, as well as community hospitals. He is unique among physician executives, having served every aspect of healthcare and related industries, including payer, provider, life sciences, government, technology, retail, employers and national security.
Co-author of “Reengineering Health Care: A Manifesto for Radically Rethinking Health Care Delivery,” Greenspun is recognized as a thought leader in the health care industry and has been named one of the “50 Most Influential Physician Executives in Healthcare” by Modern Healthcare.
Greenspun received his bachelor’s degree from Harvard University, his medical degree from the University of Maryland, and completed his residency and fellowship at the Johns Hopkins University Hospital in anesthesiology and critical care medicine, serving as chief resident. He has served on the advisory boards for the World Economic Forum, Anthem, Healthcare Information and Management Systems Society (HIMSS), Tufts and George Mason universities.
A resident of the D.C. area, Greenspun lives with his wife and sons and enjoys cycling, guitar, and supporting local youth athletic and music programs.
About Calibre One
Founded in 1999 by some of the executive search profession’s most experienced recruiters, Calibre One is a leading transatlantic executive search boutique specializing in building diverse leadership teams for innovators and companies undergoing digital transformation, including broad technology, financial services, life sciences, and media. Its team members bring an exceptional level of knowledge, integrity, and tenacity to everything it does. This is underscored by Calibre One’s transparent, consultative approach and proven methodology. Calibre One offers a 360-degree view of the entire process, along with the analytics to help identify the right candidate and reduce risk. The Calibre One process includes a proprietary measure that aligns client and candidate diversity and inclusion objectives, every search, every time. Through its relentless pursuit of excellence, Calibre One leaves no stone unturned. For more information, please visit http://www.calibreone.com.
The U.S health care system maintains one of the most sophisticated health care delivery systems in the world. However, in spite of the many advances in treatment and technology, a major barrier exists: Nearly half of all U.S. adults lack the skills necessary to read, understand, and act on their own health such as how to take their medications or understand basic health care instructions. This issue is known as low health literacy. Low health literacy is a stronger predictor of health status than age, income, employment, education, race, or ethnicity. An estimated 80 million Americans have low health literacy, which not only causes medical errors, high rates of hospitalization, death, and poor health care outcomes, but is estimated to cost the U.S. economy up to $236 billion annually.
About Health Literacy Innovations:
Health Literacy Innovations (HLI) creates tools to reduce medical mistakes, unnecessary health care costs, and poor health outcomes from low health literacy. HLI’s flagship product, the Health Literacy Advisor™ (HLA) (in Spanish–Asesor de Comunicación en Salud™), is a state-of-the-art interactive health literacy software tool available in multiple platforms, including a web-based model. As a “health literacy checker,” the HLA revolutionizes the labor-intensive health literacy review process by leveraging powerful software to help communicators evaluate, standardize, and produce clear health information. The uniquely-built HLA blends best in-class features for plain language and health literacy compliance that include English and Spanish readability indices, an interactive plain language search-and-replace function, usability, and document assessment tools that rewards users for good work, and more. For more information, please contact [email protected] or call 301-230-4966.
“Unquestionably, artificial intelligence is an integral part of the equation for unlocking significant value in healthcare through its proven ability to increase savings and boost efficiency for healthcare organizations,” stated Dr. Musheer Ahmed, Founder of AI for PI and CEO of Codoxo. “We are thrilled to introduce the AI for PI Community at the upcoming symposium to support the exploration and growth of AI for delivering better outcomes in payment integrity.”
While attending the Symposium for Artificial Intelligence in Healthcare Payment Integrity, attendees will learn about and discuss how AI is transforming outcomes across the payment integrity spectrum, how payers are approaching their AI strategies, and how executives can create a roadmap to adopting AI that will create exponential savings and improved outcomes over near- and long-term horizons. Professionals do not need to be a member of the AI for PI Community to attend this event.
Payment integrity professionals interested in the AI for PI Community are invited to join the Slack Community and follow the group on LinkedIn. More information about the Symposium is available here.
About AI for PI Community The AI for PI Community brings together healthcare payment integrity professionals to learn about and accelerate the adoption of artificial intelligence technologies and solutions that collectively and actionably reduce the rising cost of care. Through education, networking, and shared best practices and use cases, AI for PI aims to inform and inspire thousands of healthcare payer, agency, and pharmacy benefit manager (PBM) teams seeking innovative “shift-left” strategies that safeguard their bottom lines and contribute to a less costly U.S. healthcare system.
“Addressing underlying psycho-social determinants of health in the surgical window is incredibly difficult and Vx Therapy shows tremendous potential to address this unmet societal need,” says Alexander R. Vaccaro, MD, PhD, MBA, President of Rothman Orthopaedic Institute, Richard H. Rothman Professor and Chairman of the Department of Orthopaedics, and Professor of Neurosurgery at Thomas Jefferson University and Hospitals. “It will not exclude patients with underlying and/or concurrent depression and anxiety which has been clearly shown to create deleterious outcomes from a surgical standpoint.”
“We are excited to learn how technology can help the way we manage pain in surgical and non-surgical patients,” says Jose A. Canseco, MD, PhD, the study’s principal investigator, who also serves as Assistant Professor of Orthopedic and Spine Surgery at Thomas Jefferson University and Vice Chair of Research for Rothman Orthopaedics. “This study provides a comprehensive analysis of patient response to this non-pharmacological and non-interventional option to provide treatment for pain as well as provide support for the psycho-social determinants of health that are so difficult to identify and address.”
A first of its kind, this has the potential to provide a new tool for surgeons to address unmet patient needs and create better outcomes and a better patient experience. This study will evaluate the effectiveness of Vx Therapy when used in conjunction with a variety of surgical procedures.
“Vx Therapy is the first digital therapeutic platform to address not only symptoms of pain and trauma, but to address patients holistically,” states Gerry Stanley, M.D., P-CEO, Senior Vice President and Chief Medical Officer of Harvard MedTech. “Traditional models of healthcare have focused on a bio-medical model of healthcare while Vx Therapy and this study are designed to utilize a bio-psycho-social model of healthcare, in a patient’s home, to promote recovery and resiliency.”
For Rothman Orthopaedics, research is one of the pillars of which the practice has built its long-standing success. Rothman’s world-class, award-winning spine team continues to lead the international spine community through its extensive academic involvement in numerous societies, and participating in the leadership of national organizations, including the AAOS, CSRS, NASS, LSRS, and the AO Foundation. Rothman has participated in ground-breaking research and clinical trials with the goal of advancing knowledge, developing treatments and improving outcomes for the benefit of patients. Their physicians treat problems resulting from degeneration of the cervical and lumbar discs, herniated discs, spinal stenosis, spinal deformity, tumors, trauma and instability.
For more information on Rothman Orthopaedics and their research program, please visit RothmanOrtho.com.
About Harvard MedTech
Harvard MedTech is an innovative digital health company that applies current science on how the brain works with specially designed virtual reality experiences, psychosocial support, and digital engagement. Vx® Therapy is the first modality to comprehensively integrate this unique combination of digital technologies with precision behavioral health interventions, delivered through virtual reality in the patient’s home. This virtual engagement drives high compliance, patient satisfaction, and optimal outcomes. Vx® Therapy is also affordable and scalable at a population health level. This non-invasive and non-pharmacological approach also provides data that is trackable for a clear assessment of its value to patients and healthcare providers. Visit www.harvardmedtech.com for more information.
About Rothman Orthopaedic Institute
Rothman Orthopaedic Institute is the largest musculoskeletal practice in the United States according to Becker’s Review. A world leader in the field of orthopedics, Rothman Orthopaedics partners with health systems, hospitals and physicians to build enduring musculoskeletal systems of care in communities that are high-quality, compassionate, affordable and grounded in evidence-based medicine. Rothman Orthopaedic Institute orthopedists treat patients in 37 locations and has surgical privileges at 71 facilities in Pennsylvania, New Jersey, New York and Florida. With experts in nine orthopedic sub-specialties including spine, hip & knee, foot & ankle, shoulder & elbow, hand & wrist, sports medicine, physical medicine & rehabilitation, orthopedic oncology and trauma, Rothman Orthopaedics is recognized for excellence in clinical treatment methods, research, education and technology. Consistently recognized as national and regional “Top Docs,” Rothman Orthopaedics is proud to be the official team physicians for the Philadelphia Eagles, Phillies, the Orlando Magic, The Big EAST Conference, as well as over 60 college and high school teams. For more information about Rothman Orthopaedic Institute, please visit www.RothmanOrtho.com.
Media Contact
Alexandria Hammond, Rothman Orthopaedic Institute, 1 2673531667, [email protected], Rothman Orthopaedic Institute
“RF Technologies is excited to be a part of LeadingAge 2023,” said Ron Kosek, Director of Senior Living Field Sales at RFT. “This event is an excellent opportunity for us to showcase our latest developments in real-time locating systems (RTLS), including new and innovative fall detection solutions, Bluetooth Low Energy (BLE) Nurse Call, BLE Wander Management, BLE Asset Protection, and BLE Staff Protection products.”
In addition to showcasing their solutions, RFT will also be hosting a series of presentations and demonstrations at their booth throughout the event. These presentations will provide attendees with an in-depth look at RFT’s technology and how it can be used to improve safety and security in senior living facilities.
“We look forward to connecting with other professionals at LeadingAge 2023 and sharing our knowledge and expertise with them,” said Ron. “We believe that our solutions can help senior living facilities remain safe and secure environments for residents, staff, and visitors.”
RFT has been providing safety and security solutions to senior living facilities for over 36 years and is dedicated to improving the safety and security of senior living facilities worldwide. To learn more about RFT and their solutions, visit booth 601 at LeadingAge 2023.
For questions or inquiries, please contact the RFT marketing department at [email protected].
About RF Technologies RFT is a turn-key manufacturer and provider of life safety solutions for the senior living, healthcare, education, and hospitality markets. With 11,000+ installations since their founding in 1987, RFT is a collaborative partner in designing custom-configured solutions that meet each customer’s needs and reduce their liabilities. The RFT family of solutions includes CODE ALERT® nurse call, fall detection, and wander management, SAFE PLACE® patient, staff, and asset protection, HELP ALERT® staff duress, and SENSATEC® fall management products.
Germfree Labs, recognized experts in cleanroom technology and manufacturing, specialize in the development of cutting-edge infrastructures engineered to obviate constraints. These designs enhance facilities to ensure seamless production, overcoming geographical constraints, and effectively address the regulatory challenges confronting the biotech industry today. Over the course of more than a decade, Germfree has delivered mobile and modular facility solutions on a global scale, including over 110 cleanroom installations within the United States alone.
Title21 Health Solutions, the industry leader in cell and gene therapy software, regulatory compliance, and quality management, provides an advanced, all-in-one operating platform as the backbone of this decentralized manufacturing ecosystem, ensuring compliance to the highest of industry standards, increasing production capacity, and enhancing product quality and safety.
Germfree and Title21 Health Solutions have joined forces to offer established products and services that seamlessly integrate and enhance current technologies. Germfree’s mobile and modular cleanrooms, combined with Title21’s digital platform, empower healthcare institutions and drug innovators to adopt decentralized manufacturing, expanding patient access at the POC in underserved areas.
A Vision for the Future:
“Together, Germfree and Title21 Health Solutions envision a future where therapies transcend geographical boundaries, ensuring universal access regardless of location or circumstances. Our commitment to state-of-the-art facility infrastructure aligns with Title21’s OS longstanding expertise, enabling decentralized manufacturing to reduce therapy costs and expand access,” says Carol Houts, Chief Strategy Officer of Germfree Labs.
“At Title21 Health Solutions, we’ve always focused on delivering innovation and ensuring quality and regulatory compliance. Partnering with Germfree Labs allows us to extend our impact in the cell and gene therapy space. Together, we are building the future of patient-centered healthcare,” adds Lynn Fischer, CEO of Title21 Health Solutions.
The partnership between Germfree Labs and Title21 Health Solutions signifies a significant milestone in cell and gene therapy manufacturing. Embracing decentralized production, these industry experts accelerate the availability of life-saving therapies, offering hope to patients worldwide.
About Germfree Labs:
Germfree Laboratories has become a globally recognized authority in cutting-edge critical environment equipment, cleanrooms, and laboratories for over six decades. The company has consistently led the way in pioneering cleanroom design and manufacturing, serving the biopharmaceutical, healthcare, and research sectors. Germfree remains resolutely committed to providing innovative solutions that significantly improve patient access to life-changing therapies. Germfree is backed by the healthcare growth equity investor, EW Healthcare Partners. www.germfree.com
About EW Healthcare Partners: With over $4 billion raised since inception, EW Healthcare Partners is one of the oldest and most respected private healthcare investment firms and seeks to make growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in New York, London and Houston. https://www.ewhealthcare.com/
About Title21 Health Solutions: Title21 Health Solutions is an ArchiMed portfolio company. ArchiMed is a leading healthcare industry focused growth equity enterprise based in New York and Lyon, France. Since 2001, Title21 Health Solutions has been dedicated to delivering easy-to-use, flexible, and integrated technology to support health care providers and the health sciences to achieve compliance, gain efficiencies and ensure high quality, ultimately, to support improvement in patient safety and care. The sole focus is developing technology to meet the specific needs of healthcare and life sciences firms, resulting in comprehensive solutions that are flexible to evolving business and regulatory requirements. Through the years, their partnerships with industry leaders have road-mapped their innovations to continue to meet the dynamic needs of the markets they serve. www.title21.com
About ArchiMed – www.archimed.group. With offices in the US, Europe, and Singapore, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific, and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include biopharmaceutical products & services, life science tools, medical devices & technologies, diagnostics, health technologies & software and consumer health. ArchiMed helps partners internationalize, acquire, innovate, and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages €5 billion across its various funds.
With this partnership, Lyric will offer Autonomize AI “co-pilots” to customers via LyricIQ, enhancing the effectiveness and efficiency of administrative staff functions in healthcare payer settings. This approach not only boosts operational efficiency but enables administrative teams to focus more on strategic tasks, alleviating the increasing challenges of workforce burnout and staffing deficits in the sector.
Potential use cases include:
Prior Authorization: AI co-pilots swiftly pre-validate claims by analyzing medical records and guidelines, expediting approvals and reducing manual effort.
Care Gap Identification and Closure: AI co-pilots scan unstructured clinical and member data to spot missed care opportunities, facilitating precise interventions to close gaps.
Risk and Quality Assessments: AI co-pilots use machine learning to classify risk and assess care quality, guiding targeted actions for better outcomes.
Case Management: AI co-pilots can expedite and aggregate data collection from diverse sources to assemble thorough case summaries, aiding case managers in making informed decisions.
As pioneers at the intersection of technology and health care, Lyric and Autonomize AI are setting new standards in health care through AI. “The fusion of our advanced generative AI technology with Lyric’s clinical content and payment accuracy expertise promises a new era in health care,” explained Ganesh Padmanabhan, CEO of Autonomize AI. “Our combined capabilities have the potential to greatly reduce the administrative burden for health plans and healthcare organizations. This will not only improve operational efficiencies but also fundamentally enhance the patient care experience.”
About Lyric:
Lyric, formerly ClaimsXten is a leading AI healthcare technology company, committed to simplifying the business of care. Over 30 years of experience, dedicated, expert teams, and top technologies help deliver up to $14 billion of annual savings to our many loyal and valued customers—including 9 of the top 10 payers across the country. Lyric’s solutions leverage the power of machine learning, AI, and predictive analytics to empower health plan payers with pathways to increased accuracy and efficiency, while maximizing value and savings. Discover more at Lyric.ai.
About LyricIQ:
LyricIQ’s AI module collects and evaluates customer data through a secure and straightforward integration. This process identifies claims trends and forms predictive models for a comprehensive review. Leveraging AI-generated insights, Lyric’s seasoned team of data scientists and clinical experts identify potential opportunities for payment error reductions, substantial cost savings, and future value realization. LyricIQ cuts through the clutter, offering a consolidated best-of-breed solution that not only focuses on data quality and algorithmic bias but also deploys AI in a responsible, ethical manner. The LyricIQ platform creates unparalleled return on investment for customers by integrating industry-leading pre-pay editing offerings—currently employed by over one hundred and ten health plans—into a seamless, end-to-end solution.
With the implementation of LyricIQ’s advanced technological capabilities, the timeline for data review, collection, and realization of savings is drastically reduced, transforming years and months into mere weeks.
About Autonomize AI:
Going beyond the boundaries of traditional data analytics, Autonomize AI excels in organizing, contextualizing, and summarizing unstructured data. This empowers healthcare knowledge teams to seamlessly automate a range of tasks, from administrative procedures to clinical workflows. Leveraging trusted generative AI within a secure and reliable framework, Autonomize AI serves as the ultimate AI co-pilot for organizations looking to efficiently scale their knowledge work. Autonomize AI is a founding member of CancerX, President Biden’s Cancer Moonshot initiative. Our customers include Top 20 pharma, F100 Payers and life sciences companies. Visit autonomize.ai to learn more.
